CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Inclusion Criteria:

Patients must meet all of the following inclusion criteria before enrollment:
Histologically or cytologically confirmed PTCL (all subtypes) or CTCL (mycosis fungoides/Sezary syndrome) as defined by 2016 World Health Organization (WHO) classification.

For patients with PTCL:

Patients must have relapsed/refractory disease to one or more systemic therapies.
Patients with CD30-positive lymphoma must have received, be ineligible for, or intolerant to brentuximab vedotin.
Patients with limited prior exposure to Bendamustine (less than 2 full cycles or ≤ 480 mg/m2) may be included, based on PI discretion.
Patients must have measurable disease (e.g., a tumor mass >1 cm or evidence of bone marrow involvement).

For patients with CTCL, Stage IB-IVB mycosis fungoides or Sezary syndrome are eligible

Patients must have relapsed/refractory disease to at least one previous systemic therapy. Psoralen plus ultraviolet light therapy (PUVA) is not considered to be a systemic therapy.
Male and female patients 18 years of age and older
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Expected survival greater than 3 months.
Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation.
Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.
At least 2 weeks must have elapsed from prior chemotherapy drugs (other than steroids) or radiation
At least 6 weeks must have elapsed from prior autologous stem cell transplant and 12 weeks must have elapsed from prior allogeneic stem cell transplant.
Laboratory values ≤2 weeks must be: Adequate hematological function (absolute neutrophil count [ANC] ≥1,500/mm3, platelets ≥100,000/mm3). In subjects with known bone marrow involvement, ANC must be ≥ 1000/mm3 and platelets ≥75,000/mm3; Adequate hepatic function (aspartate aminotransferase [AST/SGOT] less than or equal to 3x upper normal limit [UNL], alanine aminotransferase [ALT/SGPT] less than or equal to 3x UNL (≤5x UNL if liver metastases present), bilirubin less than or equal to 1.5x UNL); Adequate renal function (serum creatinine less than or equal to 1.5 mg/dL or 133 µmol/L).
No evidence of current infection.
Mentally competent, ability to understand and willingness to sign the informed consent form.

Exclusion Criteria:

Patients with the following characteristics are excluded:
Known cerebral metastases, central nervous system (CNS) or epidural tumor.
History of prior malignancy and considered to be at greater than 30% risk of relapse
Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of treatment with study drugs (steroids are allowed)
Patients with a history of allogeneic transplant must not have ≥ grade 3 graft-versus-host disease (GVHD) or any clinically significant GVHD requiring systemic immunosuppression.
Serious medical illness that would potentially increase patients' risk for toxicity.
Pregnant women, or women of child-bearing potential not using reliable means of contraception (because the teratogenic potential of CPI-613 is unknown).
Lactating females.
Fertile men unwilling to practice contraceptive methods during the study period.
Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.
Unwilling or unable to follow protocol requirements.
Active heart disease including but not limited to symptomatic congestive heart failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic myocardial infarction or symptomatic congestive heart failure.
Evidence of current infection..
Patients with known HIV infection, hepatitis B, or hepatitis C with positive viral load.
Patients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatment.